Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus different-dose neoadjuvant chemotherapy in resectable NSCLC (Phase II)
ChiCTR2000039863Phase 2Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Changzhou Second People's Hospital. Primary endpoints: Major pathological response (MPR) rate, Blood routine and 12 more. Started Nov 2020; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000039863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039863.